Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label combination study of JNJ-3989 + JNJ-6379 + nucleos(t)ide analogs + peginterferon alfa-2a in virologically suppressed chronic hepatitis B
2020-003956-34Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2020
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tomligisiran, cetrelimab, tenofovir disoproxil fumarate, tenofovir alafenamide, entecavir and 1 more in Chronic Hepatitis B (CHB), sponsored by Janssen Pharmaceutical. Primary endpoint: Proportion of participants with at least 2 log10 IU/mL reduction in HBsAg from baseline to Week 24. Started Dec 2020; status: completed.
02
Drugs
tomligisirancetrelimabtenofovir disoproxil fumaratetenofovir alafenamideentecavir
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on 2020-003956-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003956-34.